Aligos therapeutics to host kol event to discuss the positive phase 1b data from alg-000184 for the treatment of chb

South san francisco, calif., july 10, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual kol event featuring mark sulkowski, md, johns hopkins university school of medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis b (chb), positive data from the phase 1b study of alg-000184, development plans, and the chronic suppression regulatory pathway on thursday, july 18, 2024 at 3:00pm et/12:00pm pt.
ALGS Ratings Summary
ALGS Quant Ranking